Interleukin-27 Functional Duality Balances Leishmania Infectivity and Pathogenesis

Abdollah Jafarzadeh1,2, Maryam Nemati2,3†, Prashant Chauhan4†, Ashok Patidar4, Arup Sarkar5, Iraj Sharifi6 and Bhaskar Saha4,5†

1 Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran, 2 Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rasisjan University of Medical Sciences, Rasisjan, Iran, 3 Department of Haematology and Laboratory Sciences, School of Para-Medicine, Kerman University of Medical Sciences, Kerman, Iran, 4 National Centre for Cell Science, Pune, India, 5 Trident Academy of Creative Technology, Bhubaneswar, India, 6 Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran

IL-27 is a cytokine that exerts diverse effects on the cells of innate and adaptive immune systems. Chiefly expressed in macrophages and dendritic cells during the early phase of Leishmania infection, IL-27 contributes to the protection against L. major infection but suppresses the protective Th1 response against L. donovani, L. infantum, L. amazonensis and L. braziliensis infections, suggesting its functional duality. During the late stage of Leishmania infection, IL-27 limits the immunopathogenic reactions and tissue damages. Herein, we analyze the mechanism of the functional duality of IL-27 in the resistance or susceptibility to Leishmania infection, prompting IL-27 for anti-Leishmanial therapy.

Keywords: EBI3, IL-27, Leishmania, p28, WSX-1

INTRODUCTION

IL-27 is a heterodimer of p28 and Epstein-Barr virus-induced gene 3 (EBI3) subunits and signals through IL-27-receptor complex, a heterodimer of IL-27α WSX-1 and gp130 subunits (1). The major producers of IL-27 are activated antigen-presenting cells (APCs), including DCs and macrophages (2, 3). Signaling axes, including TLR4-MyD88-AP1/c-Fos, TLR4-MyD88-IRF1/IRF8-NF-κB-c-Rel, TLR3/TRIF-IRF3/IRF7, IFN-γ-MyD88-IRF8, and IFN-α/IFN-β-STAT-1/STAT-2-IRF1/IRF9 induce the p28 expression (4–7). However, p38MAPK overexpression activates c-Fos that inhibits p28 expression (2, 8). By stimulating the C-Jun N-terminal kinases (JNK), MAPKs, and the phosphoinositide-3-kinase (PI3K), signaling IFN-γ induces IL-27 expression in human monocytes (5). The EBI3 expression is induced by the signaling axes TLR2/TLR4/TLR9-MyD88-NF-κB/PU.1 (9–11) (Figure 1). Although IL-27 is secreted as p28-EBI3 heterodimers, the IL-27p28 subunit can be secreted without EBI3, p28 (or IL-30) may work as IL-27 antagonist while working through IL-27α (12) but may work as an agonist through IL-6 receptor; the mechanism behind these contrasting effects remains unclear (13). The IL-27α exhibits the cellular and tissue/organ specificity for IL-27 effector functions. Various cells including activated B cells, activated endothelial cells, DCs, macrophages, mast cells, monocytes, naive T cells, NK cells, express IL-27R (12, 14, 15). The diversity of IL-27R-mediated intracellular functions depends on the activation of different isoforms of JAK and STAT present in the immune cell subsets: For instance, JAK-1, JAK-2, Tyrosine kinase-2 (TYK-2), STAT-1, −2, −3, −4, and −5 in naïve CD4+ T cells, JAK-1, STAT-1, STAT-3, and STAT-5 in NK cells, STAT-1 and STAT-3 in monocytes, and STAT-3 in mast cells.
IL-27 FUNCTIONS IN INNATE AND ADAPTIVE IMMUNE SYSTEMS

Upon stimulation with TLR ligands, IFNs and CD40-ligand, DCs, and macrophages release IL-27 that work in an autocrine and paracrine manner to mount innate and adaptive immune responses in several diseases; by contrast, many pathogens induce the synthesis of IL-27 in these cells.

Effects of IL-27 on Innate Immunity

IL-27 promotes NK cell cytotoxicity through upregulation of perforin and granzyme B expression (2) and supports the IFN-γ production by inducing T-bet, a transcription factor, and by enhancing the IL-18 responsiveness (19). IL-27 treatment of mast cells and eosinophils enhances their adhesion and survival and induces the production of pro-inflammatory cytokines such as IL-1, TNF-α, and IL-6 (20). IL-27 limits neutrophil recruitment and reduces IL-6 and IL-12 secretion from these cells (21). IL-27 enhances the differentiation of monocytes into macrophages, stimulates macrophages to produce nitric oxide, and induces moDCs to express IL-27, IL-8, CXCL10, chemokine receptor (CCR1), IRF8, and IFN-stimulated genes (3). IL-27-pretreated monocytes show activated STAT-3 and NF-κB phosphorylation, elevated TLR4 expression, and with LPS co-treatment, increase IL-6, TNF-α, MIP-1α, and MIP-1β expression (22). By contrast, IL-27 induces the expression of the immunosuppressor indoleamine 2,3-dioxygenase (IDO) in humans monocytes (18, 23).

IL-27 inhibits DC functions, as WSX-1-deficient DCs are hyper-reactive to LPS and promote NK cells and T cells to produce higher amounts of IFN-γ than that induced by wild-type DCs (24). IL-27 pre-treatment of DCs reduces the LPS-stimulated expression of the MHC-II and costimulatory molecules—CD40, CD86—perhaps due to IL-27-induced elevated CD39 expression (24, 25). B7-H1 (PD-L1), which provides suppressive signals to T cells, is upregulated by IL-27 in DCs (10, 26, 27). Consistent with these observations, IL-27 reduces HLA-restricted antigen presentation and inhibits proliferation and cytokine production of alloageneic T cells (28). Through STAT-1 activation (29), IL-27 inhibits proliferation and cytokine production by type-2 Innate lymphoid cells (ILC2)—a specialized cell-type that lacks antigen-specific receptors but produces high levels of helper T-cell cytokines and lipid mediators in response to antigen-independent stimuli. ILC2 express GATA3 and partake in airway inflammation via the production of type-2 cytokines. A summary of the effects of IL-27 on innate immune cells is shown in Figure 3A.

Abbreviations: AhR, aryl hydrocarbon receptor; AP1, activator protein 1; APC, antigen presenting cell; CCR, C-C chemokine receptor; CL, cutaneous Leishmaniasis; CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; CXCL, chemokine (C-X-C motif) ligand; DC, dendritic cell; DCL, diffuse cutaneous Leishmaniasis; EBI3, Epstein-Barr virus-induced gene 3 (EBI3) subunits; ERK, extracellular signal-regulated; GAS, gamma interferon activation site; IDO, inoleamine-2,3-dioxygenase; IFN, interferon; IRAK, interleukin-1 receptor; ISRE, interferon-sensitive response element; JAK/STAT, Janus kinase/signal transducers and activators of transcription; JNK, Jun kinase; LPS, lipopolysaccharide; LTR, leucine-rich repeats; MAL, MyD88 adaptor-like protein; MAPK, mitogen-activated protein kinases; MCL, mucocutaneous Leishmaniasis; MHC, major histocompatibility complex; MIP, macrophage inflammatory proteins; MKK, mitogen-activated protein kinase; moDCs, monocyte-derived dendritic cells; MyD88, MyD88 innate immune signal transduction adaptor; NAP-1, nucleosome assembly protein; NET, neutrophil extracellular traps; NF-κB, nuclear factor Kappa-light-chain-enhancer of activated B cells; NK cells, natural killer cells; NKT, natural killer T cells; NO, nitric oxide; NOX, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase; p38MAPK, p38 mitogen-activated protein kinases; PAMPs, pathogen-associated molecular patterns; PD-1, programmed cell death protein 1; PD-L2, programmed cell death ligand 2; PI3K, phosphoinositide 3-kinase; PKD1, post-kala-azar-dermal Leishmaniasis; PKD2, Post-kala-azar dermal Leishmaniasis; PRR, pattern recognition receptors; RNI, reactive nitrogen intermediates; ROR-γt, RAR-related orphan receptor gamma; ROS, reactive oxygen species; SOCS, suppressor of cytokine signaling; STAT, signal transducer and activator of transcription; TCR, T-cell receptor; TGF, transforming growth factor; TLR, toll-like receptor; TNF-α, tumor necrosis factor alpha; TRAM, TRIF-related adaptor molecule; TRIF, TIR-domain-containing adapter-inducing interferon-β; VL, visceral Leishmaniasis.
Transcriptional Control of IL-27 Synthesis. Antigen experienced immune cells (APCs, DCs, and macrophages) act as sources of IL-27. Various cellular receptors such as Toll-Like Receptors (TLR4), IL-1βR, and CD40 promote IL-27 synthesis. The expression of IL-27 subunits from APCs can be induced using TLR.

(Continued)
the presence of TGF-β and IL-2, in the peripheral tissues, respectively. Treg cells express the transcription factor FoxP3 and are characterized by the secretion of immunosuppressive cytokines TGF-β, IL-10, and IL-35 (38). The iTReg were divided into two subgroups, including Tr1- and Th3-cells, which are characterized by the production of the large amounts of IL-10 and TGF-β, respectively (39). Indeed, IL-27 supports the development of immune-regulatory Tr1 CD4+ T cells (40). IL-27 also promotes the development of IL-10, producing T-bet+ CXCR3+ Treg cells (41). IL-4 and TGF-β elicit naïve CD4+ T cells differentiation to Th9 cells, which express the transcription factor PU.1 and secrete large amounts of IL-9 that contribute to mast cell activation, induction of allergic reactions, and immune responses to intestinal helminth infections (42). IL-27 inhibits the development of Th9 cells (43). IL-6 and IL-21 elicit the T follicular helper (Tfh) cell differentiation from naïve CD4+ T cells. Tfh cells express Bcl6—a transcription factor—and provide CD40L, ICOS, and IL-21 signals required for B cell proliferation and differentiation (44). IL-27 promotes Th cell polarization and induces IL-21 (45), which promotes B cell expression of Bcl-6 and Blimp-1 that are critical for plasma cell differentiation and B cell function. Although IL-27 induces B cell proliferation and antibody production, it does not seem to promote the formation of memory B cells (46).

CD8+ T cells recognize viral- and tumor-derived antigenic peptides presented by MHC-I molecules and play a fundamental role in the killing of virally infected and cancer cells. IL-27 enhances the proliferation of naïve CD8+ T cells and the production of IFN-γ and granzyme B (47) (Figure 2). IL-27 thus differentially affects the functions of immune cells in both innate and adaptive immune systems. The effects of IL-27 on adaptive immune cells is summarized in Figure 3B.

![Figure 1](image.png)

**FIGURE 1** | agonists Poly(I:C), lipopolysaccharide (LPS), and CpG-DNA, for TLR3, TLR4, and TLR9, respectively. (A) The expression of the IL27p28 subunit can be induced through signals coming from the TLR4/MyD88/AP-1/c-Fos signaling axis. (B) Other signaling axes that culminate in the induction of IL-27p28 synthesis are TLR3/TLR4-TRIF-IRF3/IF7; IFN-γ/MyD88/IRF8 and IFN-α/IFN-β/STAT1/STAT2-IRF1/IRF9. (C) IFN-γ can induce IL-27 expression via stimulating JNK, MAPKs, and PI3K signaling. (D) EB3 expression is induced by signaling through TLR2/TLR4/TLR9-MyD88-NF-κB/PU.1. (E) Both p50 and p65 can bind to the EB3 promoter. (F) Exogenous stimuli from IL-1β or CD40-CD154 ligation can also trigger IL-27 synthesis in a MyD88 dependent fashion. Besides NF-κB, c-Rel, recruitment of PU.1, and IRF1 and IRF3 are essential events that regulate IL-27 synthesis by shaping its transcriptional landscape. Both IFN-γ, along with IFN-α and IFN-β are reported to be associated with p28 expression in DCs.

### The Role of IL-27 in Leishmania Infection

*Leishmania* is a protozoan trypanosomatid parasite and is transmitted by the sand fly vectors. *Leishmania* exists as extracellular, flagellated motile promastigotes in sand flies and as sessile, aflagellate, amastigotes within the mammalian macrophages in skin, liver, spleen, bone marrow, and mucosal tissues. It causes a complex of diseases called Leishmaniasis to affect 12 million people worldwide and one billion at risk (48, 49). Depending on the invading specie of *Leishmania*, tissue tropism of the parasite, the site and the route of infection and pathophysiology, Leishmaniasises are classified into cutaneous (CL), mucocutaneous (MCL), diffuse cutaneous (DCL), visceral (VL), and post-kala-azar dermal Leishmaniasis (PKDL) (49). The CL is the most prevalent form of the disease (70–75%), caused by *L. major* and *L. tropica* in the Middle East and North Africa, while *L. mexicana* and *L. braziliensis* are predominant in South America (49, 50). *L. amazonensis* causes DCL and CL with disseminated lesions. *L. donovani* and *L. infantum* cause VL that disseminates to spleen, liver, and bone marrow (51). Thus, *Leishmania* species differ in their growth kinetics, the tissue of infection, and clinical outcomes. Although macrophages serve as the host for all these *Leishmania* sp., the immunopathology of *Leishmania* is greatly affected by tissue-specific non-immune cells. IL-27 plays a complex role in the immuno-pathology of Leishmaniasis (52).

### Do Leishmania Salivary Gland Proteins (SGPs) Affect IL-27 Secretion?

Most species of *Leishmania* are transferred through the phlebotomine sand-fly vector. The metacyclic promastigotes are embedded in proteophosphoglycan-rich promastigote secretory gel (PSG) secreted by themselves in the anterior midgut of sandflies. PSG must be regurgitated along with infective promastigotes before sand flies can begin hemagoghy on host skin. In turn, this event leads to the accumulation of PSG, *Leishmania* along with sand-fly saliva containing SGPs on host skin. Since the first description of sand-fly SGPs disease-exacerbating function in CL (53), these are shown to induce cytokines and chemokines with potential contrasting functions (54). Many proteins including LJM19, a novel 11-kDa protein, are identified as anti-Leishmanial vaccine candidates (55, 56). Although IL-27-inducing SGPs are not reported, some probable pathways may be proposed. First, as the sand-fly bite is rich in immunomodulatory components like CD39 family ecto-apyrases converting ATP and ADP to AMP and Pi (57), the adenosine receptors on the infected DC and macrophages may modulate IL-27 secretion (58). Second, as platelet activation is associated with the chemotactic migration of effector monocytes, a potent source of IL-27, to the sites of *L. major* infection (59) an axis of SGPS-platelets activation-monocyte recruitment may modulate IL-27 production affecting the outcome of *Leishmania* infection. Third, salivary homogenates from *Lutzomyia longipalpis* suppress the costimulatory molecule expression and CD40L-induced DCs maturation (60), which may lower available IL-27 pools as observed with IL-10 and TNF-α. A limitation with such studies is that these do not highlight the exact specific composition of sand-fly salivary gland extracts, which may be composed of more than 35 secreted proteins (61). Fourth, although a vasoactive peptide (maxadilan) from the *L. longipalpis* saliva is shown to indeed increased production of prostaglandin E2 (PGE2)
FIGURE 2 | Various Extracellular Cues Can Induce IL-27 Signaling In STAT-1, STAT-3, AND STAT-5 Dependent Manner. (A) IL-27 is heterodimeric cytokine comprised of p28 and Epstein-Barr virus-induced gene 3 (EBI3) subunits. (B) IL-27 exerts its specific effects in immune cells through binding to its receptor IL-27R (comprised of... (Continued)
(62) and reciprocally modulate TNF-α and IL-6 production from BALB/c macrophages in a PGE₂-dependent manner (62), the regulation of IL-27 by maxadilan and a correlation between PGE₂ and IL-27 in experimental Leishmaniasis require further investigation. Similarly, SP15-like protein, D7-related proteins, lufaxin (reversible inhibitor of factor Xa of coagulation cascade), palmitoyl-hydrolase, and YRP proteins (57) may modulate the host IL-27 production by previously unexplored...
mechanisms. More research is needed to confirm the definitive roles of salivary gland homogenates in immunosuppression and interception of the IL-27 secretion axis in the case of Leishmania sp. infection.

The Role of IL-27 in L. major Infection

L. major infection results in polarization of the Th cells to either IL-12-dependent host-protective IFN-γ secreting Th1 cells or IL-4-dependent disease-promoting IL-10 and IL-4 secreting Th2 cells in resistant or susceptible mouse strains, respectively (63). The L. major-infected BALB/c mice display high IL-17 levels, and IL-17 deficiency or IL-17 neutralization results in a reinforced host-protective anti-Leishmanial response (64). IFN-γ and TNF-α synergistically induce the expression of inducible nitric oxide synthase (iNOS) that catalyzes nitric oxide production in macrophages to eliminate Leishmania (65, 66). The iNOS-deficient mice are vulnerable to L. major infection despite the presence of robust Th1 cell response, indicating an essential role of NO in limiting Leishmania infection (63, 67). Adding the effects of IL-27 in these complex inter-regulated circuits develops a better understanding of the CL. High levels of IL-27 expression are observed in L. major infection in vivo. The p28 expression increases at the second week, whereas EBI3 expression becomes measurable in the fifth week in the L. major-infected C57BL/6 mice (68). CD11c+ DCs express both IL-27 subunits, including p28 and EBI3, in the draining lymph nodes of L. major-infected C57BL/6 mice at 24 h post-infection (69) (Figure 4). Therefore, exogenous delivery of IL-27 into L. major-infected BALB/c mice exhibits protection by direct suppression of Th2 response and induces protective Th1 response.

IL-27 Treatment Suppresses Th2 Responses and Protects the Host From L. major Infection

The IL-27 signaling via WSX-1 contributes to protection against L. major infection (69–71). Upon IL-27 treatment, IL-27 transgenic mice are protected against L. major infection (34). The daily IL-27 administration during the first seven days after L. major infection of BALB/c mice reduces the parasite load...
and increases the survival rate compared with control mice (34). The lymph node cells from L. major-infected IL-27-treated BALB/c mice secrete higher quantities of IFN-γ and produce lower amounts of IL-4 in comparison with the cells from control mice (34). Therefore, the exogenous IL-27 protects L. major-infected BALB/c mice from CL by direct suppression of the Th2 cell responses accompanied by the induction of host-protective Th1 cell responses, perhaps due to its ability to augment IFN-γ production from NK and CD4+ T cells (70, 71). The L. major-infected macrophages from patients with healing forms of lesions produce a higher amount of IL-27 and IL-23 as compared with patients having non-healing forms of the lesion, suggesting that IL-27 and IL-23 may play synergistic roles with Th1 cytokines in protection against Leishmaniasis (72). L. major lyse-stimulated lymphocytes from EB13−/− mice secrete fewer IFN-γ and high IL-4, IL-10, and IL-13 as compared to the lymphocytes from the control mice on the second and third week post-infection. Thus, at early time points after infection, the Th1/Th2 cell balance in EB13−/− mice is diverted toward Th2 cells (69).

**IL-27 Deficiency Impairs Host-Protective Th1 Responses and Induces Susceptibility to L. major Infection**

In WSX-1−/− mice both IFN-γ production and resistance to L. major are impaired (69, 71). EB13−/− C57BL/6 mice also display greater susceptibility to L. major infection compared to C57BL/6 wild-type mice, with the maximum differences in the parasites loads and lesion sizes at the sixth-week post-infection; the lesions and parasite load are reduced from the eighth week, and lesions are entirely resolved till 14th week in EB13−/− mice (69). Rechallenge of healed EB13−/− mice with L. major does not lead to the elicitation of the pathological symptoms, indicating that the expansion and persistence of the protective immunologic memory are not impaired in EB13−/− mice (69). These observations suggest the importance of EB13 for early control of parasite replication (Figure 4). Similarly, when compared with wild-type mice, the lymph node cells from WSX-1−/− mice produce fewer IFN-γ initially but makes up the deficiency in the later stages of the infection. However, both WSX-1−/− and wild-type mice successfully control the parasite and resolve the cutaneous lesions (71). Susceptibility to L. major infection in WSX-1−/− mice is restricted to the initial stages of infection when a considerable level of IL-4 is produced (71). The anti-IL-4 mAb administration during the early stages of infection improves the IFN-γ-dependent host resistance in Leishmania infected WSX-1−/− mice. The treatment of the WSX-1−/− mice with blocking anti-IL-4 antibody also reduces the T. cruzi parasite burden and also increases the number of IL-17+ CD4+ cells, indicating that IL-4 inhibits the Th17 cell development in parasitic infections (73, 74). The initial IL-4 production during L. major infection determines the necessity for IL-27 in the induction of Th1 cell responses to limit the CL (Figure 4). However, IL-27 is not required to maintain an extended Th1 response during the later stages of L. major infection. Although WSX-1−/− mice show significant lesions at an early phase of infection, at later stages of infection it ultimately limit parasite loads and resolve the infection (70, 71). Accordingly, the increased susceptibility of WSX-1−/− mice to L. major is accompanied by the Leishmania-induced IL-4 production initially; therefore, blockade of IL-4 during the initial phase of infection abolishes the early requirement for IL-27 for the development of effective anti-parasitic responses. At 6–8 weeks post-infection, IFN-γ production is increased, and the IFN-γ/IL-4 ratio shifts toward Th1 cells in WSX-1−/− and wild type mice, which were accompanied by parasite killing and lesion resolution (69). The early EB13 expression is vital for the quick generation of effective Th1 cell-mediated immunity, but healing and immunologic memory develop in an IL-27-independent manner (69).

**IL-27 Contributes to Early Development and Maintenance of Th1 Cells and Mediates Immunity Against L. major**

It is proposed that IL-27 is initially produced by the parasite-stimulated phagocytes and skews Th1 response before IL-12 production is upregulated (75). Indeed, the IL-27-stimulated T cells express IL-12R and are then differentiated to Th1 cells in the presence of IL-12 in vivo (34). Early production of IL-27 may result in Th1 cell differentiation, and later on, maintained by IL-12 produced from L. major-infected DCs (76). Therefore, L. major-infected DCs sequentially produce IL-27 and IL-12 to establish and maintain protective Th1 cell-mediated protective immunity against this pathogen. Delayed IL-12 production during L. major infection may cause a delay in the initiation of Th1 responses (77). Indeed, WSX-1 expression diminishes in differentiated Th1 cells; contrastingly, IL-12R is still abundantly expressed in activated Th1 cells. Th1 cells from WSX1−/− mice display normal IFN-γ production in response to IL-12. Therefore, IL-27 is necessary for the early development of Th1 cells, and IL-12 is necessary for early differentiation, establishment, and full activation of Th1 cells. IL-27 causes Th1 cell differentiation through the induction of p38MAPK that upregulates T-bet. Moreover, it promotes the expression of ICAM-1/LFA-1 adhesion molecules to induce ERK1/2-related signaling pathways. Induction of both signaling pathways causes IL-12Rβ2 expression, which promotes the Th1 differentiation and IFN-γ production in the presence of IL-12 (2). WSX-1-related signaling also induces STAT1-dependent expression of T-bet and trigger IFN-γ production (78), and WSX-1−/− mice display defects in IFN-γ expression (71). IL-27R-deficient mice exhibit enhanced Th2 cell-dependent asthmatic manifestations (79). Consequently, IL-27 determines the suppression of Th2 cell response. IL-27 inhibits Th2 cell differentiation and associated cytokine-production from fully activated Th2 cells (12). IL-27 also directly inhibits GATA-3 expression in a STAT1-dependent pathway (80). IL-27 reduces GATA-3 expression while inducing T-bet expression even in polarized Th2 cells (34).

**Regulatory Effects of IL-27 During L. major Infection**

Severe lesions are reported in L. major-infected WSX-1−/− mice, which were associated with the appearance of the IL-17+ CD4+ cells, indicating a role for IL-27 in preventing the improper...
IL-27 tips the balance of immunity towards *L. donovani* survival. (A) *L. donovani* amastigotes invade hepatic macrophages (Kupffer cells). This event is followed by the invasion of leukocytes, neutrophils, monocytes, and T cells under the influence of chemotactic factors like CCL3, CCL2, and CXCL3 secreted by infected Kupffer cells. (B) These immunological reactions lead to the formation of a granuloma that is abundant in pro-inflammatory factors (IFN-γ, TNF-α, and RNI/ROS secreted by Th1 cells, NK cells, and CD8+ T cells); under such conditions *L. donovani* infection is resolved over time. (C) However, the abundance of IL-4 and IL-10 decreased iNOS expression, high production of IgG1/IgG2a ratio, and delayed maturation of granuloma, depletion of neutrophils results in high parasite load. (D) Elevated IL-10 secreted by Treg cells also contributes to *L. donovani* survival. (E) Splenic CD11c^hi^ MHC-II^hi^ DCs from *L. donovani*-infected C57BL/6 mice show high levels of IL-27. Similarly, *L. donovani* infection in BALB/c mice produces IL-27. In this case, CD8^α+^ and CD4^+^ DCs are the major producers. (F) In WSX-1^−/−^ C57BL/6 mice, a potent Th1 cell-linked response exhibits a severe hepatic inflammation (showing necrosis and deposition of reticulin fiber and collagen) that eventually resolves. In this context, IL-27-linked signals may suppress the Th1 response directly or indirectly, which helps in the suppression of hepatic inflammation by modulating the function of CD4^+^ T cells. (G) IL-27 supports the IL-10 production by IFN-γ producing Th1 cells in a pathway that involves the induction of STAT-1, STAT-3, and NOTCH signaling. (H) IL-27 also alters methylation patterns in the IL-10-gene promoter in CD4^+^ T cells that increase IL-10 expression directly. (I) IL-27, along with IL-21, enhances the differentiation of IL-10 producing TR1 cells during VL.

Development of Th17 cells during Leishmaniasis (68). The IL-17-deficient BALB/c mice exhibit smaller lesions during *L. major* infection, although a modest reduction in their parasite load is observed (64). The addition of rIL-27 to *L. major* lysate-stimulated CD4^+^ T cells collected at the eighth week post-infection from *L. major*-infected C57BL/6 mice enhances the population of IL-10^+^ IFN-γ^+^ CD4^+^ cells and IL-10^+^ IFN-γ^-CD4^+^ cells. As compared with the wild-type C57BL/6 mice, WSX-1^−/−^ C57BL/6 mice display a low percentage of IL-10^+^ IFN-γ^-CD4^+^ cells and more severe lesions 6 weeks after *L. major* infection (68). Therefore, the development of more severe lesions in the *L. major*-infected WSX-1^−/−^ mice may partly be attributed to the downregulation of the anti-inflammatory cytokine IL-10. IL-27 does not interfere with IFN-γ, TNF-α, or IL-17 production by the soluble *Leishmania* antigens (SLA)-stimulated PBMCs from patients with CL and MCL. PBMC cultures from patients with CL and MCL when supplemented with IL-27 do not show any change in the production of IL-10 (81). These findings indicate that the cytokine-producing cells from patients with CL and MCL are unresponsive to the regulatory effects of IL-27.

**IL-27 Is Dispensable for Maintaining Extended Protective Th1 Cell Response Against *L. major***

IL-27 expressed by the infected-phagocytes and DCs during the early phase of *L. major* infection contribute to the protection during the initial stage of *L. major* infection, while considerable levels of IL-4 are present and IL-4-induced Th2 cell responses are dominant (82). The protective effects of IL-27 may be exerted through inhibition of IL-4 production, prevention of Th2 cell response (34), and induction of the IFN-γ production from CD4^+^ T and NK cells, which reinforces Th1 cell responses. However, IL-27 is not necessary to maintain an extended protective Th1 cell-related response during the late stage of...
L. major infection (70). IL-27 limits tissue damages and immunopathology during L. major infection via preventing the improper Th17 cell responses (68) and induction of the immunoregulatory cytokine IL-10. Based on the discussion above, the regulatory effects of IL-27 during L. major infection are compiled and summarized in Figure 4.

The Role of IL-27 in L. donovani Infection
A large number of the L. donovani-infected persons are asymptomatic because they develop an effective T-cell-mediated immune response against the parasite (51). Accordingly, the prevalence of visceral Leishmaniasis (VL) is low, and recuperated patients are mainly protected against reinfection. Several genetic parameters, helminth infections, and malnutrition are associated with susceptibility to VL (63). L. donovani amastigotes initially infect the liver macrophages, namely as Kupffer cells (Figure 5). Then the leukocytes, especially neutrophils, monocytes, and T cells infiltrate into the liver and form granulomas that are essential in controlling the hepatic infection. The Th1 cell-related cytokines, particularly IFN-γ and TNF-α, induce the ROS and reactive nitrogen intermediates (RNI) in Kupffer cells that contribute to the parasite elimination (Figure 5). L. donovani also infects the macrophages of spleen and bone marrow (51). Splenic chronic infection is associated with modification in the lymphoid compartments, apoptosis in T cells, and unresponsiveness to parasite antigens. The TNF-α-deficient mice and anti-TNF-α antibody-treated mice did not exhibit the changes in the marginal zone macrophages after L. donovani infection, demonstrating the essential role that TNF-α plays in the alterations of the spleen compartments (83). L. donovani also stimulates splenic regulatory DCs to secrete great amounts of IL-10 after in-vitro stimulation (84).

IL-27-Linked Signals May Influence the Infection Outcome Against L. donovani by Direct or Indirect Suppression of the Protective Th1 Cell-Mediated Immune Responses
The depletion of neutrophils during the initial stages of L. donovani infection results in the high parasite load in the bone marrow and spleen, leading to splenomegaly, delayed maturation of hepatic granulomas, and a decrease the iNOS expression within the granulomas. Along with enhanced IL-10 and IL-4 quantities (85), high IgG1/IgG2a ratio against L. donovani, and elevated IL-10 production by Treg cells, the susceptibility to VL is associated with the inability to induce active cell-mediated immunity against L. donovani (86). The IL-10 neutralization promotes IFN-γ and TNF-α production and decreases the parasite load (87). L. donovani infection is not well-established in IL-10-defective mice, and the blocking of IL-10-related signaling enhances anti-parasitic immunity (87). L. donovani induces the differentiation of Th17 cells, which secrete cytokines, such as IL-17 and IL-22. The L. donovani-derived antigens stimulate PBMCs from healthy individuals to produce IL-17 and IL-22, in vitro (88). The Th1 and Th17 cells may perform complementary roles in protecting against L. donovani infection so that the impairment in the Th17 cell functions causes susceptibility to VL (88, 89). The splenic CD11chi MHC-IIhi DCs collected on day 21 and day 28 from L. donovani-infected C57BL/6 mice express high IL-27 levels (Figure 5). The L. donovani infection in BALB/c mice promotes IL-27 expression by splenic CD8α+ and CD4+ DCs on days 1, 14, and 28 post-infection (90). These results revealed that different DC subsets might be the primary IL-27 secreting cells during L. donovani infection. The circulating IL-27 quantities are elevated in L. donovani-infected humans, and splenic myeloid cells act as major producers of IL-27 (91). Indeed, the WSX-1−/− C57BL/6 mice show resistance to L. donovani infection; in addition, it effectively controls parasite load compared to wild-type mice (92). The WSX-1−/− C57BL/6 mice generate a potent Th1 cell-linked response that limits parasite growth; however, these L. donovani-infected mice display severe hepatic inflammation that eventually resolves. IL-27-linked signals may indirectly or directly suppress the protective Th1 cell-mediated immune responses against L. donovani infection (Figure 5).

IL-27 Deficiency Correlates With Robust Th1 Cell Response After L. donovani Infection
It was observed that the liver and spleen from L. donovani-infected WSX-1−/− C57BL/6 mice show lower parasite loads compared with the wild-type mice on days 15 and 30 after infection (92). By day 60 after infection, both WSX-1+/+ and WSX-1−/− mice efficiently control L. donovani loads in their liver and spleen. However, parasite loads in the liver are significantly lower in WSX-1−/− mice (92). Therefore, IL-27 is dispensable for the development of immunity against L. donovani but delays the resolution of the parasite infection. Apart from this, the L. donovani-infected WSX-1−/− mice display higher serum levels of IFN-γ and TNF-α on day 15 post-infection, more elevated serum IL-12 levels on day 30 post-infection compared with WSX-1+/+ mice (92). Levels of IL-12, TNF-α, and IFN-γ decline in L. donovani-infected WSX-1−/− mice by day 60. Nonetheless, the L. donovani-infected WSX-1+/+ mice produce more IL-10 at all examined time points when compared with WSX-1−/− mice, but differences were not significant (92). The Leishmania antigen-stimulated spleen cells from L. donovani-infected WSX-1−/− mice produce more amounts of IFN-γ and IL-12 on day 30 post-infection and generate greater levels of NO on days 15 and 30 after infection in comparison to WSX-1+/+ mice. The splenocytes from WSX-1−/− mice also produce more IL-10, indicating that IL-10 may be involved in the limiting of splenic but not hepatic inflammation in WSX-1−/− mice following L. donovani infection (92). IL-4 is not produced by L. donovani antigen-stimulated spleen cells from both mouse strains at all-time points examined (92). These findings demonstrate that WSX-1−/− mice establish a strong Th1 cell response after L. donovani infection.

IL-27 Plays a Critical Role in Suppressing Hepatic Inflammation but Does Not Impart Protection Against L. donovani Infection
Contrary to L. major infection, IL-27-related signaling is not required for the induction of the protective Th1 cell responses during L. donovani infection. There are some differences between L. donovani and L. major regarding the clinical, pathological, and immunological aspects. L. major infection in
humans usually causes self-resolving cutaneous lesions, whereas *L. donovani* infection is related to systemic manifestations of parasite spreading in organs such as the liver, spleen, and bone marrow (63) (Figure 5). Although Th1 polarization is key to the protection from *L. major* infection, the protection against *L. donovani*-mediated visceral Leishmaniasis is associated with mixed Th1- and Th2-type cytokine responses; as a result, the cured VL patients display a mixed Th response (93). Although IL-4 is a vulnerability factor in mouse *L. major* infection, it is necessary for efficient vaccine-induced protection against *L. donovani* infection (93). WSX-1−/− mice display severe liver pathology after *L. donovani* infection. WSX-1−/− mice exhibit severe liver pathology with large granulomas associated with diffuse foci of inflammation and necrosis, as well as more deposition of collagen and reticulin fiber on days 15 and 30 after infection compared with wild-type mice (92). Therefore, IL-27 plays a critical role in suppressing hepatic inflammation during the acute phase of VL. As mentioned, *L. donovani*-infected WSX-1−/− mice produce greater levels of IL-12, IFN-γ, and TNF-α during the early phase of infection in comparison to wild-type mice. The depletion of CD4+ T cells or neutralization of both TNF-α and IFN-γ also reduces the severity of liver pathology in WSX-1−/− mice but renders them susceptible to *L. donovani* (92). Hence, the IL-27-mediated pathways suppress the tissue inflammation associated with VL by modulating the CD4+ T-cell function (Figure 5). However, blockade of IFN-γ or TNF-α alone is not sufficient to block liver inflammation or compromise host resistance in WSX-1−/− mice (92). Therefore, IFN-γ or TNF-α production alone may not be adequate to induce immunopathology in the liver. These findings demonstrate that the IL-27-related pathways, in contrast to its protective role in *L. major* infection, are involved in the pathogenesis of *L. donovani* infection.

**Immunomodulatory Effects of IL-27 During *L. Donovani* Infection**

It has been indicated that the IL-10+ IL-27+ DCs can promote IL-10 production by Th1 cells in vivo (94). In *L. donovani* infected C57BL/6 mice, the frequency of splenic IFN-γ+ IL-10+ T-bet+ CD4+ T cells is increased on day 28 post-infection (94). IL-27 directly alters methylation patterns in CD4+ T cells at the IL-10 gene promoter, thus causing higher IL-10 expression (95) (Figure 5). IL-27 supports IL-10 production by IFN-γ-producing Th1 cells through STAT1, STAT4, and Notch signaling molecules via an alternate pathway (96, 97). The optimal generation of CD4+IL-10+ T cells by IL-27 requires c-Maf, Icos, and IL-21 expression (98, 99). Further, IL-27 and IL-21 together enhance the expansion and differentiation of IL-10-secreting Tr1 cells during VL (40, 51). IL-21 also reinforces the IL-10 secretion by IL-27-induced Tr1 cells (100). Therefore, IL-27 controls the severity of VL-associated inflammation by inducing anti-inflammatory cytokine IL-10. Recently, in a mouse model of *L. donovani* infection using BALB/c mice, it has been reported that the administration of the neutralizing anti-EBI3 antibody (but not anti-p28 antibody) to pathogen-infected mice reduce the parasite load in the spleen and liver, and increase the TNF-α- and IFN-γ-secreting cells (101). As EBI3 is shared by IL-35 and IL-27, it has been concluded that IL-35 may have more immunomodulatory effects during *L. donovani* infection (101). These regulatory effects of IL-27 during *L. donovani* infection are summarized in Figure 5.

Collectively, IL-27 is expressed by different DC subsets during the early phase of *L. donovani* infection, IL-27 may directly and/or indirectly suppress the protective Th1 cell-mediated responses against *L. donovani* infection, which may delay the resolution of the parasite infection. The *L. donovani*-infected WSX-1−/− mice exhibit a diversion in Th1/Th2 cells toward Th1 cell responses. During *L. donovani* infection, CD4+ T cells play a critical role in mediating hepatic damage in WSX-1−/− mice wherein IL-27 attenuates immune-pathological response-related tissue damages by inducing the expression of the anti-inflammatory cytokine IL-10 by Tr1- and Th1 cells.

**Role of IL-27 in *L. infantum* Infection**

*L. infantum* infection in humans and animal models leads to an increase in the IL-27 expression (102). High levels of the p28 subunit of IL-27 are detected in the spleen and liver of *L. infantum*-infected C57BL/6 mice at 4 and 6 weeks post-infection. The expression of both IL-27R subunits, including WSX-1 and gp130, are upregulated mainly in the fourth week after infection, indicating that the expression of IL-27 and its receptor is induced during *L. infantum* infection (103). The *in-vitro* experiments indicated that the bone-marrow-derived macrophages (BMDMs) and BMDCs from C57BL/6 mice can produce IL-27 when infected with *L. infantum* (103). The *Leishmania*-derived nucleic acids (DNA and RNA) are recognized by intracellular TLRs like TLR3, TLR7, TLR8, and TLR9 (63, 104). The BMDMs are deficient in TLR3 and TLR9 or adaptor molecules MyD88 and TRIF are not able to produce IL-27 after *L. infantum* infection, indicating that nucleic acids from *L. infantum* activate these pathways to trigger the IL-27 production. *L. infantum* infection induces IL-27 production in a consecutive process that includes the events, engagement of TLR3 and TLR9, the IFN-β induction, and activation of IRF1 that lead to IL-27 production in macrophages infected with *L. infantum*. The soluble CD40L also increases the production of several cytokines (IL-12p70, IL-23, IL-27, IL-15, and IL-1β) by *L. infantum*-infected human macrophages in *vitro* (105). A negative correlation was observed between the levels of these cytokines in the supernatants of cultured macrophages with the number of infected macrophages as well as amastigotes. *Leishmania* may also trigger sCD14 and initiate the IL-27, IL-10, and IL-6 production, which subsequently modulate macrophage microbicidal activity, facilitating *Leishmania* proliferation (106).

**IL-27 Is a Regulatory Cytokine That Dictates Susceptibility to *L. infantum* Infection**

For experimental VL both C57BL/6 and BALB/c strains are considered as susceptible models, but only BALB/c mice, not C57BL/6 mice displayed the augmented serum IL-27 levels during an early stage of *L. infantum* infection. The phenomenon was attributed to the upregulation of p28 expression by splenic DCs and higher parasite burdens in BALB/c mice.
IL-27 tips the balance of immunity towards *L. infantum* survival. IL-27 plays a role in the suppression of the protective immune response during *L. infantum* infection. (A) In EBI<sup>−/−</sup> mice, IL-27 modulates the IL-17 production and neutrophil infiltration. (B) Higher expression of powerful neutrophil chemoattractant CXCL1 is observed in the spleen of EBI3<sup>−/−</sup> mice. (C) IL-27 and its receptor expressed during the early phase of *L. infantum* infection where infected DCs and macrophages are the major producers of this cytokine in pathways originating from TLR3, TLR9, and IFN-β. (D) As Th1 and Th17 cells-related responses help combat *L. infantum* infection, IL-27 is regarded as the susceptibility factor because of its ability to interfere with Th1- and Th17-induced protection.

High expression of TLR2 by DCs from BALB/c mice may support the early IL-27 expression after infection, which contributes to the attenuating of inflammation and promoting infection (102). It has been reported that the *L. infantum*-infected BMDCs from BALB/c mice produce higher IL-27 levels than C57BL/6 mice. Whereas, the LPS-stimulated BMDCs from C57BL/6 mice produce higher amounts of IL-27 than BALB/c mice (102), indicating that parasite vigorously upregulates the secretion of IL-27 in BMDCs derived from BALB/c, but not from C57BL/6 mice. In both cutaneous and visceral forms of human Leishmaniasis, the IL-27 production is increased when the disease is in the active phase (91, 106). When compared with healthy subjects and delayed-type hypersensitivity (DTH) positive individuals, the sera from VL patients before treatment showed high levels of cytokines-IFN-γ, IL-10, IL-6, IL-27, and TNF-α. Besides, the serum levels of these cytokines decrease after treatment (106). B cell activation is also promoted by IL-27, exacerbating the hypergammaglobulinemia in VL patients (106). In a mouse model of VL, IL-27 plays a role in the suppression of the protective immune response during *L. infantum* infection, which can lead to disease exacerbation (103). IL-27 suppresses
the immune response in VL through the induction of IL-10 production in vivo (91). The IL-27 restricts the Th1 cell polarization via inducing the IL-10-producing DCs. In fact, in the p28−/− mouse model restricted to DCs, CD4+ T cell-related IFN-γ response is exacerbated (107). The collective production of both IL-27 and IL-10 by L. donovani-infected DCs is essential for IL-10 production by Th1 cells, resulting in parasite persistence (94).

IL-27 Modulates IL-17 to Affect Neutrophil Infiltration in the Spleen of L. infantum Infected Mice

The administration of rIL-27 to C57BL/6 increases the IL-10 production, while decreasing IFN-γ and IL-12p70 in the peritoneal cavity, and prevents the infiltration of neutrophils in the spleen 24 h after the treatment (102). IL-27 neutralization in acutely infected BALB/c mice reduces parasite burdens and reduces IL-10 levels, while leads to a transient increase in the splenic IFN-γ-producing CD4+ and CD8+ T cells (102). The investigations using EBI3−/− mice indicate a role for IL-27 in modulating the IL-17 production and neutrophil infiltration during the chronic phase of L. infantum infection (102, 103). The EBI3−/− mice produce considerably higher IL-17A levels than wild-type C57BL/6 mice in both spleen and liver. Restimulation of EBI3−/− mouse-derived splenocyte with L. infantum lysate leads to significant IL-17A production. IL-17A is the critical mediator of neutrophil infiltration in the spleen of infected mice (Figure 6), which induces chemoattractant-CXCL1 expression (103). Higher CXCL1 expression is observed in the spleen of EBI3−/− mice, which causes elevated neutrophil migration at the fourth week post-infection in the spleen and liver.

IL-27 Leads to Host Vulnerability to L. infantum by Reducing the Neutrophil Influx

Neutrophils have diverse mechanisms for combating pathogens, some of which include the production of cytokines and chemokines that lead to inflammmatory cell recruitment as well as the release of proteolytic-enzymes/cathepsin/neutrophil-elastase and neutrophil extracellular traps (NETs) mediated-pathogen killing (108, 109). Host resistance through neutrophils in response to Leishmania depends on both the host's genetic background as well as the invading Leishmania species (63). For example, L. amazonensis promastigotes are eliminated by NETs, while L. major may survive within neutrophils (110). The host's genetic factors also affect neutrophil performance during Leishmaniasis. The neutrophil-defective C57BL/6 mice display a common L. major infection, while neutrophil-defective BALB/c mice exhibit a weak harmful Th2 cell response (111). The neutrophil-defective Genista mice are resistant to L. mexicana that causes non-healing lesions. During VL, neutrophils play a protective role. In C57BL/6 mice during L. infantum infection, IL-17A levels are reduced in the infected organs (103). The downregulation of IL-17A is mediated by IL-27, as EBI3 deficiency leads to intensified IL-17A secretion. Upon IL-17A neutralization, the resistant EBI3−/− mice become as susceptible as the control wild-type mice, representing the ability of IL-27 to prevent the IL-17A production directly. Moreover, neutrophil infiltration is also reduced after anti-IL-17A treatment, satisfying the role of IL-17A in neutrophil recruitment to infected organs in parallel to the induction of NO production by macrophages (103). The inhibition of IL-17A by IL-27 during L. infantum infection leads to host vulnerability by reducing the neutrophil influx. Although the EBI3-deficiency impairs the Th1 responses in L. infantum-infected mice, other arms of the inflammatory response such as IL-17A and neutrophils limit the parasite load even in the absence of efficient Th1 cell response (103). Based on the discussion above, the regulatory effects of IL-27 during L. infantum infection are shown in Figure 6.

IL-27 and its receptor are expressed on the infected macrophages and DCs during the early phase of L. infantum infection. TLR3- and TLR9-, and IFN-β related signaling pathways play a prominent role in IL-27 production during L. infantum infection (Figure 6). In addition to the mouse strains, other molecules such as soluble CD40L and sCD14 also influence IL-27 production (112). In L. infantum-infected humans with VL, the IL-27 levels are increased in the active phase, and coming back to basal amounts after treatment, represent that this cytokine may be considered as a marker of VL severity or prognosis. IL-27 is a regulatory cytokine that plays a role in susceptibility to L. infantum infection. As Th1- and Th17 cell-related responses confer protection against L. infantum infection (113), IL-27 increases the susceptibility to parasite by interfering with both protective Th1 and Th17 responses.

Role of IL-27 in L. amazonensis Infection

The C57BL/6 mice are vulnerable to L. mexicana or L. amazonensis infection due to compromised Th1 cell responses (114). This inability has been attributed to elevated IL-10 production, which causes insufficient DC activation and IL-12 production. Although Th1 cell-mediated immunity limits the Leishmania infection, the Th1 cell-released cytokines like TNF-α and IFN-γ involve in the immunopathologic reactions. Indeed, elevated TNF-α and IFN-γ quantities were detected in severe CL and ML patients. L. amazonensis causes anergic DCL and CL with disseminated lesions (50). A different modulating role has been proposed for Treg cells in L. amazonensis infection. The Treg transfers from Leishmania-infected mice to naive mice shortly before L. amazonensis infection decreases lesion development signifying that the role of Treg, cells in limiting immunopathological responses (115). The results from an in-vitro analyses indicate that the expression of both IL-27 subunits, including p28 and EBI3, is augmented in L. amazonensis-infected macrophages from C57BL/6 mice measured at 4 hours after infection (116).

IL-27 Is a Susceptibility Factor During L. amazonensis Infection

In L. amazonensis-infected C57BL/6 mice, the injection of the rIL-27 into the infected footpads (on days 2, 4, and 6 prior infections) strongly enhances the lesion sizes and parasite number in the footpads and the draining lymph nodes at weeks 2 and 3 following infection (116). Although IL-27 signaling contributes to the Th1 cell-related protective response in the L. major-infected mice, the same pathway may enhance the susceptibility to L. amazonensis, perhaps
due to the differences in protein kinase R (PKR)-mediated signaling between *L. major* - and *L. amazonensis*-infected macrophages. The PKR-mediated signaling supports *L. amazonensis* but reduces *L. major* infection (117). *L. amazonensis* activates PKR in macrophages for their survival. The PKR activation by poly I:C (a ligand for TLR3) causes IL-10 production, and IL-10 neutralization prevents the parasite expansion (118), suggesting a TLR3-PKR-IL-27-IL-10 axis in *L. amazonensis* infection.

**TLR2-PKR-IFN-1 Signaling Contributes to *L. amazonensis* Survival in an IL-27 Dependent Manner**

It is reported that the addition of rIL-27 to human macrophages infected with *L. amazonensis* promastigotes augments the parasite propagation and percentage of infected cells measured on days 3 and 4 after the cytokine addition. The IL-27 neutralization or IL-10 receptor blockade in the infected cell cultures markedly reduce the parasite multiplication (116). Hence, the IL-27-related enhancing effects on *L. amazonensis* growth and survival occur mainly through IL-10. (A) Inside macrophages, *L. amazonensis* activates protein kinase R (PKR). (B) PKR activation can also occur through Poly I:C (a ligand for TLR3), which elicits IL-10 production. (C) Using anti-IL-10 antibody parasite replication could be entirely abrogated. (D) TLR2−/− macrophages express low levels of IFN-β and PKR post-*L. amazonensis* infection, indicating that the TLR2-PKR-IFN-1 axis contributes to the IL-27 production during *L. amazonensis* infection that supports parasite survival. (E) Interestingly, when produced, IL-27 triggers more PKR activation, which triggers its production by a positive feedback mechanism.
survival and growth occur mainly through IL-10. Treatment of the *L. amazonensis*-infected human macrophages with a PKR inhibitor abrogates the IL-27-mediated *L. amazonensis* replication. PKR is activated by IL-27, which is crucial to IL-27-mediated Leishmania expansion (116). TLR2-deficient C57BL/6 mice are also less susceptible to *L. amazonensis* infection than wild-type counterparts (63). TLR2−/− macrophages express low quantities of IFN-β and PKR post-*L. amazonensis* infection (63). Indeed, *L. amazonensis* infection leads to the activation of the PKR/IFN-1 axis via a TLR2-dependent manner, which promotes parasite replication in macrophages (116). Interestingly, the *Leishmania*-induced IL-27 expression also depends on the TLR2 and IFN-1-mediated signaling (119). The expression of IL-27 is profoundly diminished in infected-macrophages derived from TLR2−/− or IFN-1R−/− mice (116, 119). TLR2-PKR-IFN-1 signaling contributes to the IL-27 production in *L. amazonensis*-infected macrophages that lead to the intracellular survival of the parasite. When produced, IL-27 elicits new cycles of PKR activation, which supports parasite expansion (116). These regulatory effects of IL-27 during *L. amazonensis* infection are depicted in Figure 7.

The *L. amazonensis*-infected macrophages may be one of the main sources of IL-27 during the infection. IL-27 profoundly increases the vulnerability *L. amazonensis* infection, and its promoting effects on the parasite survival and growth occur mainly through an IL-10-dependent manner. Indeed, the TLR2-PKR-IFN-1 axis contributes to the IL-27 production during *L. amazonensis* infection that supports the survival of the parasite. When produced, IL-27 triggers more PKR activation, which stimulates its production by a positive feedback mechanism. Accordingly, the targeting of TLR2, PKR, and IFN-1 may impair the IL-27 production, which eventually diminishes the *L. amazonensis* replication.

**Role of IL-27 in *L. braziliensis* Infection**

The *L. braziliensis*-related CL is associated with robust Th1 responses (65, 120) conferring protection against the parasite. However, excessive uncontrolled inflammation is responsible for the development of skin lesions and tissue damages, as observed in ML and CL patients (118). Reduced IL-10 production along with the heightened IFN-γ and TNF-α production are positively correlated with lesions sizes and tissue damage in CL and ML (118, 121). A high number of cytotoxic cells are also observed in lesions of patients with CL caused by *L. braziliensis* and correlated with explicit inflammatory stress and cutaneous tissue damage (122). Patients treated with anti-inflammatory drugs show alleviated lesions size, supporting the deleterious role of inflammation during the *L. braziliensis* infection (65). The PBMCs from *L. braziliensis*-infected individuals with CL pattern produce higher levels of IFN-γ and TNF-α than cells from patients with subclinical (SC) pattern after *in vitro* stimulation with SLA (123). The SLA-stimulated PBMCs from patients with SC tend to express higher amounts of IL-17 compared with patients with CL pattern (124). The addition of rIL-27 to SLA-stimulated PBMCs from patients with CL reduces IFN-γ production (81, 124). Further, higher IL-10 levels were detected in *L. braziliensis*-infected individuals with SC pattern when compared with CL patients (125). Therefore, IL-10 and IL-27 may modulate the deleterious Th1 cell responses in *L. braziliensis* infection. Hence, the proper expression of the IL-10 and IL-27 may cause an asymptomatic SC form, while the low expression of IL-10 and IL-27 may lead to symptomatic CL pattern in *braziliensis*-infected individuals (Figure 8).

**IL-27 in *L. braziliensis* Infection**

IL-10 and TGF-β, but not IL-27, modulate the expression of the TNF-α, IFN-γ, and IL-17 by SLA-stimulated PBMCs from ML and CL patients (118). IL-27 was unable to enhance IL-10 production by PBMCs from CL and ML patients (81). The PBMCs from CL and ML patients are unresponsive to the immunomodulatory effects of IL-27. In skin biopsy from patients with *L. braziliensis*-related CL, the increased IL-10 and IL-27 expression were also associated with high IFN-γ expression, although a similar pattern of cytokine expression was not observed in ML group (126). A positive association has been indicated between the IL-10 expression and IL-27, IL-21, and IFN-γ expression but not with the FOXP3 expression in lesions of patients with CL (127). A new subgroup of Treg cells, namely Tr1-like cells with CD4+ CD25− CD127+/low FOXP3− phenotype was identified in the peripheral blood of *L. braziliensis*-infected patients with CL that produce higher levels of IL-10 (127). The secretion of IL-10 from CD4+ CD25− FOXP3− cells in the initial phase may suppress the Leishmanicidal mechanisms of macrophages, which supports the establishment of infection (127). However, in chronic stages, when a strong Th1 response is dominant, Tr1-like cells may help in protecting tissues from damage caused by an inflammatory reaction. The possible IL-27 contribution to the development of the Tr1-like cells needs to be further investigated. The regulatory effects of IL-27 during *L. braziliensis* infection are shown in Figure 8.

Collectively, the excessive uncontrolled Th1 cell-mediated inflammation is involved in the tissue damages in ML and CL *L. braziliensis*. The IL-27, in parallel with IL-10, attenuates the deleterious Th1 cell response during the late stage of the *L. braziliensis* infection (124). However, the precise role of the IL-27 during the early stage of *L. braziliensis* infection needs more clarification.

**CONCLUSION**

IL-27 is expressed during the early phase of *Leishmania* infection, and the infected phagocytes and DCs are the major producers of this cytokine. The role of IL-27 in *Leishmania* infection is species-dependent (Table 1). The protective role of IL-27 during the initial stage of *L. major* infection is exerted mainly through inhibition of IL-4-mediated Th2 cell responses. Therefore, evaluation of the local therapeutic potential of IL-27 or its agonists concerning the *L. major*-mediated CL requires more investigations. In mouse models of OVA-induced asthma, the intranasal IL-27 administration significantly improves the clinical symptoms of the disease, decreases the local eosinophilia in the nasal mucosa, modulates the cytokine production by Th1, Th2, and Treg cells, and decrease the
TABLE 1 | Experimental studies indicating the role of IL-27 in Leishmaniasis disease.

| Parasite species | Mouse strain | Infective dose* | Infection site | Observation                                                                 | References |
|------------------|--------------|----------------|----------------|------------------------------------------------------------------------------|------------|
| L. major         | WT C57BL/6   | 1 x 10^3 MP    | Ear dermis     | • P28 expression is increased in infected tissue at week two post-infection. | (68)       |
|                  |              |                |                | • EBI3 expression becomes detectable in infected tissue at week five post-infection. | (68)       |
| L. major         | WSX-1−/−C57BL/6 | 1 x 10^3 MP    | Ear dermis     | • The mice exhibit more severe lesions that were associated with the appearance of the IL-17+ CD4+ cells. | (68)       |
|                  |              |                |                | • IL-27 administration prevents the development of abnormal Th17 cells during Leishmaniasis. | (68)       |
|                  |              |                |                | • The mice display a low percentage of IL-10+ IFN-γ− CD4+ cells and more severe lesions at week 6 post-infection. | (68)       |
| L. major         | WT C57BL/6   | 2 x 10^3 MP    | Ear dermis     | • CD11c+ DCs express P28 and EBI3 in draining lymph nodes at 24 h post-infection. | (69)       |
| L. major         | EBI3−/−C57BL/6 | 2 x 10^3 MP    | Ear dermis     | • Mice display greater susceptibility to infections with maximum parasites loads and lesion sizes at week six post-infection. | (69)       |
|                  |              |                |                | • At weeks 2 and 4 post-infection, the IFN-γ secretion is lower, while the IL-4, IL-10, and IL-13 secretion were higher by L. major lysate-stimulated lymphocytes. | (69)       |
|                  |              |                |                | • At early time points after infection, the Th1/Th2 balance is diverted toward Th2 cells. | (69)       |
| L. major         | WSX-1−/−C57BL/6 | 2 x 10^6 MP    | Hind footpad   | • Lymph node cells produce low Leishmania-induced IFN-γ levels at the initiation of infection. | (71)       |
|                  |              |                |                | • Lymph node cells produce normal IFN-γ levels later in infection. | (71)       |
|                  |              |                |                | • Mice produce considerable levels of IL-4 at the initial of infection. | (71)       |
|                  |              |                |                | • Susceptibility to L. major is limited to the initial stages of infection. | (71)       |
|                  |              |                |                | • The IP administration of anti-IL-4 antibody (every 4 days for the first 4 weeks of after infection) improves the IFN-γ production and host resistance. | (71)       |
|                  |              |                |                | • The treatment with blocking anti-IL-4 antibody increases the number of IL-17+ CD4+ cells. | (71)       |
| L. major         | WT BALB/c    | 2 x 10^5 PM    | T.S.C into the hind footpad | • Administration of IL-27 reduces the parasite load. | (34)       |
|                  |              |                |                | • Administration of IL-27 increases the survival rate. | (34)       |
|                  |              |                |                | • Lymph node cells from IL-27-treated mice secrete higher IFN-γ quantities and lower IL-4 levels. | (34)       |
| L. donovani      | WT C57BL/6   | 3 x 10^7 AM    | Intravenously  | • Splenic CD11c^hi MHCIi^hi cDCs collected at days 21 and 28 post-infection express high IL-27 levels. | (94)       |
|                  |              |                |                | • The DC-derived IL-27 may enhance the IFN-γ+ IL-10+ CD4+ cell polarization in vivo. | (94)       |
| L. donovani      | WT BALB/c    | 2 x 10^7−6 AM  | Intravenously  | • Injection promotes the IL-27 expression by splenic CD8α+ and CD4+ DC at days 1, 14, and 28 post-infection. | (90)       |
| L. donovani      | WSX-1−/−C57BL/6 | 1 x 10^7 AM   | Intravenously  | • Mice contain fewer parasites in livers on days 15, 30, and 60 after infection. | (92)       |
|                  |              |                |                | • Mice show high resistance to L. donovani infection. | (92)       |
|                  |              |                |                | • Mice display higher serum IFN-γ and TNF-α level on day 15 post-infection. | (92)       |
|                  |              |                |                | • Mice display higher serum IL-12 levels on day 30 post-infection. | (92)       |
|                  |              |                |                | • By day 60, levels of IL-12, TNF-α, and IFN-γ drop in mice. | (92)       |
|                  |              |                |                | • The Leishmania antigen-stimulated spleen cells produce more amounts of IFN-γ and IL-12 on day 30 post-infection and produce more significant levels of NO on days 15 and 30 after infection. | (92)       |
|                  |              |                |                | • Mice mount a robust Th1 cell response after L. donovani infection. | (92)       |
|                  |              |                |                | • Mice display severe liver pathology. | (92)       |
|                  |              |                |                | • The depletion of CD4+ T cells reduces liver pathology. | (92)       |
|                  |              |                |                | • Neutralization of both TNF-α and IFN-γ reduces liver pathology. | (92)       |
| L. donovani      | WT BALB/c    | 2.5 x 10^7 AM  | Intravenously  | • Administration of the neutralizing anti-EBI3 antibody (and not anti-p28 antibody) to pathogen-infected mice reduces the parasite load in the spleen and liver and increase the TNF-α- and IFN-γ-secreting cells. | (101)      |
| L. infantum      | WT C57BL/6   | 1 x 10^6 PM    | Intravenously  | • Serum IL-27 levels are increased early (at 4 days after infection) in the BALB/c mice, but not in C57BL/6 mice. | (102)      |
|                  | WT BALB/c    |                |                | • The splenic DCs from BALB/c mice but not from C57BL/6 mice upregulate the expression of IL-27p28 24 h after infection. | (102)      |
|                  |              |                |                | • IL-27 secretion by BMDCs from BALB/c was higher compared to C57BL/6, whereas the LPS-stimulated BMDCs from C57BL/6 mice produce more elevated amounts of IL-27 than BALB/c mice. | (102)      |
|                  |              |                |                | • The administration of rIL-27 to in C57BL/6 increase the production of IL-10, while decrease IFN-γ and IL-12p70, and prevent the infiltration of neutrophils in the spleen at 24 h after treatment in comparison with infected non-treated animals. | (102)      |
TABLE 1 | Continued

| Parasite species | Mouse strain | Infective dose* | Infection site | Observation | References |
|------------------|--------------|----------------|---------------|-------------|------------|
| L. infantum      | WT C57BL/6   | $1 \times 10^7$ | PM Intravenously | • Neutralization of IL-27 in acutely infected BALB/c decreases parasite burdens transiently reduces IL-10 and a transient increase in splenic IFN-γ producing CD4+ and CD8+ T cells. | (103) |
| L. infantum      | EBI3−−/− C57BL/6 | $1 \times 10^7$ | Intravenously | • The expression of both IL-27R subunits, including WSX-1 and gp130, are upregulated at week 4 after infection. | (103) |
| L. amazonensis   | WT C57BL/6   | $5 \times 10^5$ | Hind footpad | • The IL-27 administration into the infected footpads (on days 2, 4, and 6 after infection) enhances the lesion sizes and parasite number in the footpads and the draining lymph nodes in weeks 2 and 3 following infection. | (116) |

*AM, Amastigotes; MP, Metacyclic promastigotes; PM, Promastigotes; SC, Subcutaneous.

serum levels of specific IgE (128, 129). The effects of such intranasal IL-27 administration need to be investigated in various Leishmania sp. infections.

Leishmania skew naïve T cells toward Th2 cells for its survival in the host. On the other hand, IL-27 has the capability to polarize naïve T cells to Th1 cells, which plays host protective roles by jeopardizing parasite growth in the host. Nonetheless, IL-27 may suppress the protective immune responses against L. donovani, L. infantum, L. amazonensis, and L. braziliensis. Therefore, T cell-dependent IL-27 functions are diverse, species-specific, and contradictory. At the same time, the infection and pathology of the Leishmania species are unique and vary with IL-27 dependency. The targeting of IL-27 or its receptor using blocking monoclonal antibodies, small molecule inhibitors, and siRNA, alone or in combination with other therapeutic agents, needs to be evaluated as promising strategies for the treatment of the L. donovani-, L. infantum-, L. amazonensis-, and L. braziliensis-related complications. IL-27 or IL-27 associated signaling molecules may be considered as exciting novel targets for immunomodulation in Leishmaniasis. Further, the clinical values of IL-27 as a marker of Leishmaniasis severity and/or as a monitoring marker of treatment efficacy need more considerations. It may be underlined that IL-27 possesses the potential to be a valuable biomarker for active human VL and for monitoring the effectiveness of treatment modality.

AUTHOR CONTRIBUTIONS

AJ, MN, and IS conceptualized and drafted the manuscript and Table 1. BS and AS scrutinized the scientific-content, language, grammar, and edited the manuscript. AP and PC contributed additionally to writing and reviewed the manuscript. PC conceptualized, designed, and digitalized the figures. All authors contributed to the article and approved the submitted version.

FUNDING

BS’s work was supported by the JC Bose Fellowship and Indo-Iran Bilateral Exchange Program, the Department of Science and Technology, Government of India.

ACKNOWLEDGMENTS

The authors would like to thank Prof. Tamas Laskay and Arathi Nair for their critical evaluation and valuable suggestions regarding figures and the manuscript.

REFERENCES

1. Jones GW, Hill DG, Cardus A, Jones SA. IL-27: a double agent in the IL-6 family. Clin Exp Immunol. (2018) 193:37–46. doi: 10.1111/cei.13116
2. Wang Q, Liu J. Regulation and immune function of IL-27. In: Ma X, editor. Regulation of Cytokine Gene Expression in Immunity and Diseases. Dordrecht: Springer (2016). p. 191–211.
3. Abdalla AE, Li Q, Xie L, Xie J. Biology of IL-27 and its role in the host immunity against mycobacterium tuberculosis. Int J Biol Sci. (2015) 11:168–75. doi: 10.7150/ijbs.10464
4. Molle C, Nguyen M, Flamand V, Renneson J, Trottein E, De Wit D, et al. IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3. / Immunol. (2007) 178:7607–15. doi: 10.4049/jimmunol.178.12.7607
5. Blahoianu MA, Rahimi AA, Kozlowski M, Angel JB, Kumar A. IFN-γ-induced IL-27 and IL-27p28 expression are differentially regulated through JNK MAPK and PI3K pathways independent of Jak/STAT in human monocytic cells. Immunobiology. (2014) 219:1–8. doi: 10.1016/j.imbio.2013.06.001
6. Pirhonen J, Siren J, Julkunen I, Matikainen S. IFN-α regulates Toll-like receptor-mediated IL-27 gene expression in human
macrophages. J Leukocyte Biol. (2007) 82:1185–92. doi: 10.1189/jlb.0307157

7. Molle C, Goldman M, Goriely S. Critical role of the IFN-stimulated gene factor 3 complex in TLR-mediated IL-27p28 gene expression revealing a two-step activation process. J Immunol. (2010) 184:1784–92. doi: 10.4049/jimmunol.0902005

8. Zhang J, Qian X, Ning H, Eickhoff CS, HofT DF, Liu J. Transcriptional suppression of IL-27 production by Mycobacterium tuberculosis-activated p38 MAPK via inhibition of AP-1 binding. J Immunol. (2011) 186:5885–95. doi: 10.4049/jimmunol.1003447

9. Kim HS, Go H, Akira S, Chung DH. SOCS3, a major regulator of infection and pathological immunity. J Exp Med. (2003) 198:1067–77. doi: 10.1084/jem.20030516

10. Fabbi M, Carbotti G, Ferrini S. Dual roles of IL-27 in cancer biology. Curr Opin Immunol. (2010) 22:92–8. doi: 10.1016/j.coi.2009.12.007

11. Wirtz S, Becker C, Fantini MC, Nieuwenhuis EE, Tubbe I, Galle PR, et al. EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kB activation. J Immunol. (2005) 174:2814–24. doi: 10.4049/jimmunol.174.5.2814

12. Yoshida H, Hunter CA. The immunobiology of interleukin-27. Ann Rev Immunol. (2015) 33:317–43. doi: 10.1146/annurev-immunol-032613-112134

13. Garbers C, Spudy B, Aparicio-Siegmund S, Waetzig GH, Sommer J, Holscher C, et al. An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem. (2013) 288:4346–54. doi: 10.1074/jbc.M112.432955

14. Hall A, Silver J, Hunter C. The immunobiology of IL-27. Adv Immunol. (2012) 115:1–44. doi: 10.1016/B978-0-12-394299-9.00001-1

15. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines and murine macrophages. J Leukocyte Biol. (2005) 77:101–17. doi: 10.1189/jlb.0504276

16. Conjević GM, Vuletić AM, Martinović KM, Larsen AK, Jurišić VB. The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine. (2019) 117:30–40. doi: 10.1016/j.cyto.2019.04.001

17. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol. (2005) 5:521–31. doi: 10.1038/nri1648

18. Li J, Wu H, Xing W, Yang S, Lu S, Du W, et al. Interleukin-27 as a negative regulator of human neutrophil function. Scand J Immunol. (2010) 72:284–92. doi: 10.1111/j.1365-3083.2010.02242.x

19. Peters C, Wynnck C, Guzzo C, Mehta D, Logan S, Banfield BW, et al. IL-27 enhances LPS-induced IL-1β in human monocytes and murine macrophages. J Leukocyte Biol. (2017) 102:83–94. doi: 10.1189/jlb.3A0316-098R

20. Carbotti G, Barisone G, Airoldi I, Mezzanzanca D, Bagnoli M, Ferrero S, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget. (2015) 6:43267–80. doi: 10.18632/oncotarget.6530

21. Wang S, Miyazaki Y, Shinzoaki Y, Yoshida H. Augmentation of antigen-presenting and Th1-promoting functions of dendritic cells by WSX-1 (IL-27Rα) deficiency. J Immunol. (2007) 179:6421–28. doi: 10.4049/jimmunol.179.6.6421

22. Li M-S, Liu Z, Liu Q, Zhao X, Liu Z, Bai X-F. The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy. Immunotherapy. (2015) 7:191–200. doi: 10.2217/imt.14.95

23. Murugaiyan G, Saha B. IL-27 in tumor immunity and immunotherapy. Trends Mol Med. (2013) 19:108–16. doi: 10.1016/j.molmed.2012.12.002

24. Karakhanova S, Bedke T, Enk AH, Mahnke K. IL-27 renders DC immunosuppressive by induction of B7-H1. J Leukocyte Biol. (2011) 89:837–45. doi: 10.1189/jlb.0411078

25. Morandi F, Di Carlo E, Ferrone S, Petretto A, Pistoia V, Airoldi I. IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation. J Immunol. (2014) 192:2634–42. doi: 10.4049/jimmunol.1302656

26. McChlida T, Kindermann M, Neves A, Voehringer D, Neurath M, Wirtz S. IL-27 suppresses type 2 immune responses in vivo via direct effects on group 2 innate lymphoid cells. Mucosal Immunol. (2016) 9:1384–94. doi: 10.1038/mi.2016.20

27. Villarrino AV, Larkin J, Saris CJ, Caton AJ, Lucas ST, de Sauvage FJ, et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol. (2005) 174:7684–91. doi: 10.4049/jimmunol.174.12.7684

28. Jafarzadeh et al. Functional Duality of IL-27

Frontiers in Immunology | www.frontiersin.org 18 August 2020 | Volume 11 | Article 1573
Jafarzadeh et al. Functional Duality of IL-27

63. Jafarzadeh A, Nemati M, Sharifi I, Nair A, Shukla D, Chauhan P, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. (2012) 7:e35671. doi: 10.1371/journal.pone.0035671

64. Kostka SL, Bera C, Herrero M, Desjoux P, Cano I, et al. Leishmaniasis. Frontiers in Immunology. 2019:19.

65. Scott P, Novais FO. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol. (2016) 16:581–92. doi: 10.1038/nri.2016.72

66. Olekhnovich R, Ryffel B, Müller AJ, Bousso P. Collective nitric oxide production provides tissue-wide immunity during Leishmania infection. J Clin Immunol. (2014) 12:1711–22. doi: 10.1112/jci27058

67. Wei X-Q, Charles IG, Smith A, Ure J, Fergl J, Huang F-P, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature. (1995) 375:408–11. doi: 10.1038/375408a0

68. Anderson CF, Stumhofer JS, Hunter CA, Sacks D. IL-17 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol. (2009) 183:4619–27. doi: 10.4049/jimmunol.0804024

69. Zahn S, Wirtz S, Birkenbach M, Blumberg RS, Neurath MF, von Stebut E. Impaired Th1 responses in mice deficient in Epstein-Barr virus-induced gene 3 and challenged with physiological doses of Leishmania major. Eur J Immunol. (2005) 35:1106–12. doi: 10.1002/eji.200425926

70. Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity. (2001) 15:569–78. doi: 10.1016/S1074-7613(01)60026-0

71. Artis D, Johnson LM, Joyce K, Sarris C, Villarino A, Hunter CA, et al. Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J Immunol. (2004) 172:4672–5. doi: 10.4049/jimmunol.172.8.4672

72. Tolouei S, Ghaedi K, Khamsehpour A, Akbari M, Baghaii M, Hasheminia S, et al. IL-23 and IL-27 levels in macrophages collected from peripheral blood of patients with healing vs non-healing form of cutaneous leishmaniasis. Iran J Parasitol. (2012) 7:18–25.

73. Martinez GJ, Nurieva RI, Yang XO, Dong C. Regulation and function of proinflammatory TH17 cells. Ann NY Acad Sci. (2008) 1143:188. doi: 10.1196/annals.1443.021

74. Cobb D, Smeltz RB. Regulation of proinflammatory Th17 responses during Trypanosoma cruzi infection by IL-12 family cytokines. J Immunol. (2012) 188:3766–73. doi: 10.4049/jimmunol.1103748

75. Pifanzi T, Timans JC, Cheung J, Rosales R, Kanizer H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EB15 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. (2002) 16:779–90. doi: 10.1016/S1076-7613(02)00324-2

76. Hibbert L, Pifanzi S, de Waal Malefyt R, Kastelein RA. IL-27 and IFN-α signal via Stat1 and Stat3 and induce T-Bet and IL-12Rβ2 in naive T cells. J Interferon Cytokine Res. (2003) 23:513–22. doi: 10.1089/1079990036078632

77. Belkaid Y, Mender S, Lira K, Kadambi N, Milan G, Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol. (2000) 165:969–77. doi: 10.4049/jimmunol.165.2.969

78. Hamano S, Himeno K, Miyazaki Y, Ishii K, Yamanaka A, Takeda R, et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity. (2003) 19:657–67. doi: 10.1016/S1074-7613(03)00298-X

79. Miyazaki Y, Inoue H, Matsumura M, Matsumoto K, Nakano T, Tsuda M, et al. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J Immunol. (2005) 175:2401–7. doi: 10.4049/jimmunol.175.4.2401

80. Lucas S, Ghirardi N, Li J, de Sauvage JF. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and independent mechanisms. Proc Natl Acad Sci. (2003) 100:15047–52. doi: 10.1073/pnas.253651700

81. Oliveira WN, Ribeiro LE, Schrieffe A, Machado P, Carvalho EM, Bacellar O. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis. Cytokine. (2014) 66:127–32. doi: 10.1016/j.cyto.2013.12.016

82. Chatelain R, Varkila K, Coffman RL. IL-4 induces a Th2 response in T cells through Stat1-dependent and-

Frontiers in Immunology | www.frontiersin.org 19 August 2020 | Volume 11 | Article 1573
Jafarzadeh et al. | Functional Duality of IL-27

84. Waklach A, Fournier N, Brun V, Breittmayer J-P, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunology. (2003) 18:605–17. doi: 10.1046/S0014-7613(03)01113-4

85. McElrath M, Murray H, Cohn Z. The dynamics of granuloma formation in experimental visceral leishmaniasis. J Exp Med. (1988) 167:1927–37. doi: 10.1084/jem.167.6.1927

86. Bhattacharya P, Ghosh S, Ejazi SA, Rahaman M, Pandey K, Das VN, et al. Induction of IL-10 and TGFβ from CD4+ CD25+ FoxP3+ T cells correlates with parasite load in Indian kala-azar patients infected with Leishmania donovani. PLoS Neg Trop Dis. (2016) 10:e0004422. doi: 10.1371/journal.pntd.0004422

87. Gautam S, Kumar R, Maurya R, Nylén S, Ansari N, Rai M, et al. IL-21 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis. (2011) 204:1134–7. doi: 10.1093/infdis/jir461

88. Pitta MG, Romano A, Cabantous S, Henri S, Hammad A, Kouriba B, et al. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol. (2011) 186:3977–85. doi: 10.4049/jimmunol.1003588

89. Rosas LE, SatoSkar AA, Roth KM, Keiser TL, Barbi J, Hunter C, et al. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to Leishmania donovani infection but develop severe liver immunopathology. Am J Pathol. (2006) 168:158–69. doi: 10.2353/ajpath.2006.050013

90. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid metalloproteinase-9 in serum are associated with active visceral disease in humans. J Immunol. (2010) 184:311–23. doi: 10.4049/jimmunol.0901233

91. Pot C, Jin H, Awasthi A, Liu SM, Lai C-Y, Madan R, et al. Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J Immunol. (2008) 180:2752–6. doi: 10.4049/jimmunol.180.5.2752

92. Rutz S, Janke M, Kassner N, Hoehnstein T, Krueger M, Scheffold A. Notch regulates IL-10 production by T helper 1 cells. Proc Natl Acad Sci USA. (2008) 105:4397–502. doi: 10.1073/pnas.071202105

93. Batten M, Kljavin NM, Li J, Walter MJ, de Sauvage FJ, Ghilardi N. Cutting edge: IL-27 and IL-21 synergistically regulate anti-leishmanial immunity. J Immunol. (2016) 197:1471–5. doi: 10.4049/jimmunol.1500437

94. Wu Y, Feng C, Zhang X, Lu J, Zhao Y. The diverse biological functions of neutrophils during Leishmania donovani infection. Front Immunol. (2017) 8:1437. doi: 10.3389/fimmu.2017.01437

95. Ortega-Caballero S, Rada L, Bresciani T, Verbalis JG, Lazo JP, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol. (2010) 11:854. doi: 10.1038/ni.1912

96. Nascimento AAH, Rippel M, de Andrade FC, de Almeida LP, de Sousa CR, et al. IL-27 regulates IL-10 production by T helper 1 cells. Proc Natl Acad Sci USA. (2008) 105:6748–53. doi: 10.1073/pnas.0900226105

97. Yang F, Feng C, Zhang X, Lu J, Zhao Y. The diverse biological functions of neutrophils during Leishmania donovani infection. Front Immunol. (2017) 8:1437. doi: 10.3389/fimmu.2017.01437

98. Ortega-Caballero S, Rada L, Bresciani T, Verbalis JG, Lazo JP, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol. (2010) 11:854. doi: 10.1038/ni.1912

99. Nascimento AAH, Rippel M, de Andrade FC, de Almeida LP, de Sousa CR, et al. IL-27 regulates IL-10 production by T helper 1 cells. Proc Natl Acad Sci USA. (2008) 105:6748–53. doi: 10.1073/pnas.0900226105

100. Asad M, Sabur A, Shadab M, DIDWANIA N, ALI N. EB1-3 chain of IL-35 along with TGF-β synergistically regulate anti-leishmanial immunity. Front Immunol. (2019) 10:616. doi: 10.3389/fimmu.2019.02049

101. Peréz-Cabezás B, Cenicco P, Robalo AL, Silvestre R, Farrill E, Moreno J, et al. Interleukin-27 early impacts Leishmania infantum infection in mice and correlates with active visceral disease in humans. Front Immunol. (2016) 7:478. doi: 10.3389/fimmu.2016.00478

102. Velasquez LG, Galuppo MK, De Rezende E, Brandao WN, Peron JP, Uliana A, et al. Cutting edge: IL-27 (IL-27) mediates susceptibility to visceral Leishmaniasis by suppressing the IL-17–neutrophil response. Infect Immun. (2016) 84:2289–98. doi: 10.1128/IAI.00283-16

103. de Freitas EO, de Leoratti FMS, Freire-de-Lima CG, Morrot A, Feijó DF. The contribution of immune evasive mechanisms to parasite persistence in visceral leishmaniasis. Front Immunol. (2016) 7:153. doi: 10.3389/fimmu.2016.00153

104. de Oliveira Barreto FA, Bonfim AS, Leite LGS, dos Santos TRS, dos Santos PL, de Almeida RP, et al. Soluble CD40 ligand in sera of subjects exposed to Leishmania infantum infection reduces the parasite load in macrophages. PLoS ONE. (2015) 10:e0141265. doi: 10.1371/journal.pone.0141265

105. de Oliveira Barreto FA, Bonfim AS, Leite LGS, dos Santos TRS, dos Santos PL, de Almeida RP, et al. Soluble CD40 ligand in sera of subjects exposed to Leishmania infantum infection reduces the parasite load in macrophages. PLoS ONE. (2015) 10:e0141265. doi: 10.1371/journal.pone.0141265

106. de Oliveira Silva FA, Damascena CVO, Passos NP, Duthe RO, Guederian MS, Bhatia JA, et al. High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis. J Infect Dis. (2016) 213:620–7. doi: 10.1002/hep.26166

107. de Oliveira Silva FA, Damascena CVO, Passos NP, Duthe RO, Guederian MS, Bhatia JA, et al. High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis. J Infect Dis. (2016) 213:620–7. doi: 10.1002/hep.26166

108. de Oliveira Silva FA, Damascena CVO, Passos NP, Duthe RO, Guederian MS, Bhatia JA, et al. High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis. J Infect Dis. (2016) 213:620–7. doi: 10.1002/hep.26166
118. Bacellar O, Lessa H, Schriefer A, Machado P, de Jesus AR, Dutra WO, et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun. (2002) 70:6734–40. doi: 10.1128/IAI.70.12.6734-6740.2002

119. de Carvalho Vivarini R, Pereira MS, Dias Teixeira KL, Calegari-Silva TC, Bellio M, Laurenti MD, et al. Human cutaneous leishmaniasis: interferon-dependent expression of double-stranded RNA-dependent protein kinase (PKR) via TLR2. FASEB J. (2011) 25:4162–73. doi: 10.1096/fj.11-185165

120. Skeiky Y, Benson DR, Guderian JA, Whittle JA, Bacelar O, Carvalho EM, et al. Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun. (1995) 63:4105–14. doi: 10.1128/IAI.63.10.4105-4114.1995

121. Antonelli LR, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett. (2005) 101:226–30. doi: 10.1016/j.imlet.2005.06.004

122. Novais FO, Carvalho AM, Clark ML, Carvalho LP, Beiting DP, Brodsky IE, et al. CD8+ T cell cytotoxicity mediates pathology in the skin by inflammasome activation and IL-1β production. PLoS Pathog. (2017) 13:e1006196. doi: 10.1371/journal.ppat.1006196

123. Ivonise F, Cibele A, Olivia B, Clarissa BA, Lucas PC, Roque PA, et al. Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis. (2002) 34:e54–8. doi: 10.1086/340261

124. Novoa R, Bacellar O, Nascimento M, Cardoso TM, Ramasawmy R, Oliveira WN, et al. IL-17 and regulatory cytokines (IL-10 and IL-27) in L. braziliensis Infection. Parasite Immunol. (2011) 33:132–6. doi: 10.1111/j.1365-3024.2010.01256.x

125. Bittar RC, Nogueira RS, Vieira-Gonçalves R, Pinho-Ribeiro V, Mattos MS, Oliveira-Neto MP, et al. T-cell responses associated with resistance to Leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis. Memorias Insti Oswaldo Cruz. (2007) 102:625–30. doi: 10.1590/S0074-02762007005000069

126. Costa DL, Cardoso TM, Queiroz A, Milanezi CM, Bacellar O, Carvalho EM, et al. Tr-1-like CD4+ CD25−/lowFOXp3− cells are the main source of interleukin 10 in patients with cutaneous leishmaniasis due to Leishmania braziliensis. J Infect Dis. (2015) 211:708–18. doi: 10.1093/infdis/jiu406

127. Suzuki M, Yokota M, Ozaki S, Matsumoto T. Intranasal administration of IL-27 ameliorates nasal allergic responses and symptoms. Int Arch Allergy Immunol. (2019) 178:101–5. doi: 10.1159/000493398

128. Liu X, Li S, Jin J, Zhu T, Xu K, Liu C, et al. Preventative tracheal administration of interleukin-27 attenuates allergic asthma by improving the lung Th1 microenvironment. J Cell Physiol. (2019) 234:6642–53. doi: 10.1002/jcp.27422

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Jafarzadeh, Nemati, Chauhan, Patidar, Sarkar, Sharifi and Saha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.